Exosomal circRNAs in cancer: Implications for therapy resistance and biomarkers

Zhengjun Lin1, Yuqiao Ji1, Jian Zhou2

  • 1Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China; Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, People's Republic of China.

Cancer Letters
|May 29, 2023
PubMed

Insights

Circular RNAs (circRNAs) in exosomes are key drivers of cancer therapy resistance. Targeting these exosomal circRNAs offers a promising strategy to overcome treatment failure and improve cancer patient outcomes.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Cancer therapy resistance is a major obstacle to curative treatments.
  • Circular RNAs (circRNAs) are stable, noncoding RNAs found in exosomes.
  • Exosomal circRNAs can influence cancer progression and treatment response.

Purpose of the Study:

  • To review the mechanisms by which exosomal circRNAs mediate resistance to various cancer therapies.
  • To explore the therapeutic potential of exosomal circRNAs as biomarkers and drug targets.
  • To discuss future prospects and challenges in targeting exosomal circRNAs for cancer treatment.

Main Methods:

  • Literature review of studies on circRNAs, exosomes, and cancer therapy resistance.
  • Analysis of molecular mechanisms of exosomal circRNA involvement in chemotherapy, targeted therapy, immunotherapy, and radiotherapy resistance.
  • Synthesis of current research on the clinical applications of exosomal circRNAs.

Main Results:

  • Abnormally expressed exosomal circRNAs are implicated in resistance to multiple cancer treatments.
  • Exosomal circRNAs can be transferred between cancer cells, affecting their behavior.
  • These molecules play roles in cancer proliferation, migration, and immune evasion.

Conclusions:

  • Exosomal circRNAs represent a significant mechanism driving cancer therapy resistance.
  • Targeting exosomal circRNAs is a potential strategy to reverse resistance and improve therapeutic efficacy.
  • Further research is needed to fully harness exosomal circRNAs as biomarkers and therapeutic targets in oncology.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K